ging interpretations of generally accepted accounting principles; the availability of capital resources, including in the form of capital markets financing opportunities, in light of industry developments affecting issuers that have pursued a "reverse merger" with an operating company based in China, as well as general economic conditions; and other relevant risks detailed in the Company's filings with the Securities and Exchange Commission.
This announcement contains translations of certain Renminbi amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from Renminbi to U.S. dollars as of and for the periods ending March 31, 2012 were made at the noon buying rate of RMB6.2975 to $1.00 on March 30, 2012 in the City of New York for cable transfers in Renminbi per U.S. dollar as certified for customs purposes by the Federal Reserve Bank of New York. China Cord Blood Corporation makes no representation that the Renminbi or U.S. dollar amounts referred to in this press release could have been or could be converted into U.S. dollars or Renminbi, at any particular rate or at all.
For more information, please contact:China Cord Blood CorporationMs. Joeling LawTel: (+852) 3605-8180Email: email@example.com ICR, Inc.Mr. Rob KoeppTel: (+86) 10-6583-7516U.S. Tel: (646) 405-5185EXHIBIT 1CHINA CORD BLOOD CORPORATIONUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETSAs of March 31, 2011 and 2012
(in thousands except share data)March 31,March 31,20112012RMBRMBUS$ASSETSCurrent assetsCash and cash equivalents
611,387794,311126,131Accounts receivable, less allowance for doubtful accounts (March 31, 2011: RMB11,850; March 31, 2012: RMB13,916)
6,7296,6661,059Prepaid expenses and other receivables
-35456Deferred tax assets
Page: 1 2 3 4 5 6 7 8 9 10 11 Related biology technology :1
|SOURCE China Cord Blood Corporation|
Copyright©2012 PR Newswire.
All rights reserved
. China Integrated Energy Inc. Completes Independent Investigation2
. China Biologic Products Names Chairman David Gao to Additional Post of CEO3
. China Pharma Holdings, Inc. to Report First Quarter of Fiscal Year 2012 Financial Results on May 15, 20124
. China Biologic Has Announced the Resignation of CFO Y. Tristan Kuo and Named Mr. Ming Yang as Interim CFO5
. China Cord Blood Corporation Announces Completion of $65 Million Convertible Debt Financing with KKR6
. Sigma-Aldrich Opens New Wuxi Packaging and Quality Control Facilities to Enhance Capabilities Serving China and Asia-Pacific Region7
. China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 20128
. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China9
. Elsevier Launches Bilingual International Nursing Skill Training and Management Platform: NursingChina.com10
. 3SBio Inc. to Present at the UBS Greater China Conference 201211
. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports